United States Alzheimer's Disease Therapeutics Market 2033 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The global alzheimer's disease therapeutics market size reached US$ 24.27 billion in 2024 and is expected to reach US$ 46.47 billion by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/alzheimers-disease-therapeutics-market?sb

Key Development:

United States: Recent Alzheimer's Disease Therapeutics Developments

✅ In December 2025, Eisai and Biogen announced LEQEMBI® IQLIKTM (lecanemab‐irmb) subcutaneous injection maintenance dosing is now available in the U.S. for early Alzheimer's disease patients, expanding at‐home treatment options and supporting long‐term disease management.

✅ In November 2025, the U.S. Food and Drug Administration approved LEQEMBI® IQLIKTM subcutaneous injection for maintenance dosing, marking the first anti‐amyloid treatment with an at‐home injection option for early Alzheimer's disease, enhancing patient‐centric care.

✅ In November 2025, the NIH released its 2025 Alzheimer's Disease and Related Dementias Progress Report, outlining expanded research investments and initiatives to accelerate precision‐medicine therapeutic discovery and clinical trials in the U.S. research ecosystem.

✅ In October 2025, new clinical and safety data on continuous lecanemab treatment showed sustained disease‐modifying effects, reinforcing confidence in long‐term anti‐amyloid therapy strategies.

✅ In August 2025, Sanofi completed the acquisition of Vigil Neuroscience, Inc., a U.S. biotech developing an oral TREM2 agonist (VG‐3927) for Alzheimer's disease, strengthening its early‐stage neurology pipeline and expanding its neurodegenerative therapeutics capabilities.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=alzheimers-disease-therapeutics-market

Japan: Recent Alzheimer's Disease Therapeutics Developments

✅ In December 2025, LEQEMBI® (lecanemab) was officially set to launch in Japan on December 20, giving patients access to a disease‐modifying treatment shown to slow cognitive and functional decline in early Alzheimer's disease.

✅ In November 2025, Eisai submitted a new drug application to the PMDA for a subcutaneous formulation of LEQEMBI®, aiming to bring the first at‐home injection option for Alzheimer's therapy to Japanese patients pending approval.

✅ In October 2025, real‐world and clinical trial evidence on lecanemab's performance confirmed pharmacological effects on neurotoxic amyloid‐β protofibrils, supporting broader treatment adoption in Japan and globally.

✅ In August 2025, Japan's health authorities prepared for broader regulatory actions around Alzheimer's therapeutics, including considerations toward pricing, approval pathways and patient access frameworks for advanced dementia treatments.

Key Players:

=> Eli Lilly and Company, Pfizer Inc., Merck & Co., Inc., Eisai Co., Ltd., Merz Therapeutics, Otsuka Pharmaceutical Co., Ltd., Alpha Cognition, and Johnson & Johnson Services, Inc., among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/alzheimers-disease-therapeutics-market?sb

Key Segments:

By Stage

Early-stage Alzheimer's (Mild) accounts for the largest share, estimated at 42%, driven by early diagnosis initiatives, increasing awareness, and the adoption of disease-modifying therapies to slow progression. Middle-stage Alzheimer's (Moderate) holds 35% share, supported by growing patient population requiring symptomatic management and supportive care interventions. Late-stage Alzheimer's (Severe) represents 23%, primarily associated with advanced care requirements, including long-term institutionalization and complex therapeutic regimens.

By Drug Class

Cholinesterase Inhibitors dominate the market with 38% share, owing to their established efficacy in improving cognitive function and daily living activities. NMDA Receptor Antagonists account for 27%, used predominantly for moderate-to-severe Alzheimer's to manage cognitive decline. Combination Drugs hold 21%, driven by the increasing trend toward multi-targeted therapies that address both cognitive and behavioral symptoms. Immunotherapy represents 14%, reflecting the rising investment in disease-modifying treatments targeting amyloid-beta and tau proteins, with significant potential for future growth.

By Region

North America leads the market with 45% share, driven by high healthcare expenditure, strong research pipelines, early diagnosis programs, and regulatory approvals for innovative Alzheimer's therapies. Europe holds 28%, supported by aging populations, healthcare infrastructure, and increasing adoption of standard-of-care treatments. Asia-Pacific accounts for 17%, driven by growing awareness, government initiatives, and expanding healthcare access. South America represents 6%, supported by urbanization and increasing disease prevalence. Middle East & Africa holds 4%, primarily influenced by rising healthcare investments and awareness programs.

Market Outlook (2024-2031)

The Alzheimer's therapeutics market is projected to grow steadily through 2031, fueled by rising prevalence, early detection, and the development of novel drug classes such as immunotherapies. Ongoing research, regulatory support, and increasing geriatric populations are expected to drive demand across North America, Europe, and emerging regions in Asia-Pacific and South America. Multi-targeted therapies and combination drugs present significant growth opportunities, especially for early- and middle-stage Alzheimer's patients.

FAQ

What is the current size of the Alzheimer's Disease Therapeutics Market?

A: In 2024, the Alzheimer's Disease Therapeutics Market was valued at US$ 24.27 billion, reflecting its strong industry presence.

Q2: How large is the Alzheimer's Disease Therapeutics Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Alzheimer's Disease Therapeutics Market will grow to around US$ 46.47 billion , demonstrating significant expansion.

Q3: What is the growth rate of the Alzheimer's Disease Therapeutics Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 7.5% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.